budesonide MMX (Uceris) vs hydrocortisone acetate (Cortifoam)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: Glucocorticoid receptor · full Ulcerative Colitis pipeline
budesonide MMX (Uceris)
Marketed by Bausch Health and partners
NCT00679380 · Phase 3 · completed
This was a randomized, fully blinded, placebo-controlled trial of 514 patients with a clinical and endoscopic remission endpoint. The primary comparison was met for the 9 mg dose but not for the 6 mg dose, so the trial gives a split result across the two doses tested.
Reported efficacy
Number of Participants Who Achieved Clinical Remission at Day 56 (Baseline up to Day 56): Registered primary, clinical remission at day 56 (UCDAI rectal bleeding and stool frequency subscores of 0), budesonide MMX 9 mg vs placebo added to oral mesalamine: 56/230 vs 52/228 (CT.gov); similar in both groups, p=0.70 (Rubin 2017). Combined clinical and endoscopic remission at week 8: 13.0% vs 7.5%, p=0.049. (missed)
Result source: NCT01532648
hydrocortisone acetate (Cortifoam)
Marketed by Viatris
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Ulcerative Colitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | budesonide MMX (Uceris) | hydrocortisone acetate (Cortifoam) |
|---|---|---|
| Clinical remission (induction) | —Not reported | —Not reported |
| Clinical remission (maintenance) | —Not reported | —Not reported |
| Clinical response (induction) | —Not reported | —Not reported |
| Endoscopic improvement (induction) | —Not reported | —Not reported |
| Corticosteroid-free remission (maintenance) | —Not reported | —Not reported |
Clinical remission (induction)
- budesonide MMX (Uceris)
- —Not reported
- hydrocortisone acetate (Cortifoam)
- —Not reported
Clinical remission (maintenance)
- budesonide MMX (Uceris)
- —Not reported
- hydrocortisone acetate (Cortifoam)
- —Not reported
Clinical response (induction)
- budesonide MMX (Uceris)
- —Not reported
- hydrocortisone acetate (Cortifoam)
- —Not reported
Endoscopic improvement (induction)
- budesonide MMX (Uceris)
- —Not reported
- hydrocortisone acetate (Cortifoam)
- —Not reported
Corticosteroid-free remission (maintenance)
- budesonide MMX (Uceris)
- —Not reported
- hydrocortisone acetate (Cortifoam)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
hydrocortisone acetate (Cortifoam): no structured comparison results are available for Ulcerative Colitis.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: budesonide MMX (Uceris)'s landscape · hydrocortisone acetate (Cortifoam)'s landscape